Pictet Asset Management (Switzerland)’s Coherus Oncology CHRS Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CHRS Stock Details CHRS Fund Activity

Upgrade to unlock

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$6.1M	Buy
2023 Q1	$5.84M	Buy
2022 Q4	$2.46M	Buy
2022 Q3	$2.23M	Buy
2022 Q2	$1.22M	Buy
2022 Q1	$1.6M	Sell
2021 Q4	$2.53M	Hold
2021 Q3	$2.55M	Buy